Preparing Your Submission

You can read Wiley's Preparing Your Article resource for general information about preparing a submission.

Submitting your manuscript via the Wiley Authors Dashboard

All submissions to this journal must be made through the Wiley Authors Dashboard. The dashboard brings the full author workflow — from starting a submission through to publication into one place.

You can begin your submission by selecting the Start Submission button on the journal's For Authors page or by following the journal's submission link below:
https://submission.wiley.com/journal/NDD2

If you have previously used our submission systems, any bookmarks you have saved will automatically redirect to the Wiley Authors Dashboard. No additional setup is required.

The Wiley Authors Dashboard provides:

• A single location to submit and manage manuscripts
• Access to your inprogress and past ‑submissions
• Clear actions to take for any tasks requiring your attention
• A consistent experience across all Wiley journals

If you have questions about the dashboard or the submission process, you can consult the help widget or refer to our support documentation.

Article types

Neuro-Drug Discovery publishes the following types of submissions:

• Original Research
• Review
• Short Communication
• News and Views
• Letter to the Editor
• Editorial (by invitation)
• Commentary
• Clinical Guideline
• Consensus
• Technical Report
• Study Protocol
• Practice and Policy
• Meta-Analysis
• Case Report
• Perspective

Peer Review Model

We follow a single-anonymized peer review model for applicable article types.

Except where otherwise stated, manuscripts are peer reviewed by at least two anonymous reviewers and an Associate or Assistant Editor.

Papers authored by Editors or Editorial Board members of the journal will be handled by Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias.

Standardizing the terminology across journals and publishers used to describe peer review practices makes the peer review process for articles and journals more transparent and enables the community to better assess and compare peer review practices between different journals.

To support transparency and scalable drafting, the journal uses the following peer review descriptors:

Identity transparency: Single-anonymized

You can learn about the different types of peer review on Wiley's Author Services website. To learn more, read Wiley's review policy.

Submission Preparation Checklist

This checklist includes the information you need to provide at submission and whether it should be included directly in the main document or uploaded separately on the submission platform.

The submission system will show you where to provide these details after you click "start your submission".

*Please provide figures in the highest resolution possible, whether this means they are embedded in the main document or provided separately.

You may also provide:

• Cover letter
• Registered Reports
• Embedded rich media
• Suggested X post
• Cover image submission
• Research Resource Identifiers (RRIDs)
• Sequence data

Note: You can read more about these in the "Submission preparation details" section.

Submission Preparation Details

Cover Letter

Cover letters are not mandatory, but you can upload one as a separate document at submission if you would like to include one.

Cover letters should be short and indicate the rationale for your submission and how it will advance the community. Cover letters are not shared with reviewers and will remain confidential between authors and editors.

Main Document

The manuscript should be editable .doc/.docx or LaTeX (.tex) file including text and tables. Please provide figures in the highest resolution possible, whether this means they are embedded or provided separately.

Note: If the manuscript, figures, or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the Editorial Office will send them back for revision.

If submitting your manuscript file in LaTeX format via Wiley Authors, select the file designation "Main Document – LaTeX .text File" on upload. When submitting a LaTeX Main Document, you must also provide a PDF version of the manuscript for Peer Review. If submitting your manuscript in LaTeX format via Wiley Authors, you may upload a .zip file containing the main .tex file, a compiled PDF, and all supporting files (e.g., figures, bibliographies). This ensures all necessary components are included for peer review and production Please upload this file as "Main Document – LaTeX PDF." All supporting files that are referred to in the LaTeX Main Document should be uploaded as a "LaTeX Supplementary File." We recommend reviewing Wiley's New Journal Design (NJD) LaTeX Authoring Template.

The main document for a research article should be presented in the following order:

• A title page
• Abstract (if relevant)
  • Indicate the abstract's word limit and whether the abstract is structured (include required subheadings) or unstructured.
• Up to 7 keywords
  • Keywords may include acronyms as well as brief phrases common to your field of research
• Main text, formatted as:
  1. Introduction
  2. Materials & Methods
  3. Results
  4. Discussion
  5. Conclusion
• References
• Tables
  • Each table complete with title and footnotes
• Figures
• Figure legends:
  • Figure captions can be included at the end of your main document if figures are submitted as separate files. Clarify journal formatting for legends by defining all abbreviations in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
• Appendices (if relevant)

Note: Supporting materials should be submitted as separate files.

Title Page

The title page should include:

• A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips)
• A short running title of less than 40 characters
• The full names of the authors
• Co-author details, including affiliation and email address

Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.

• Any statements relating to our ethics and integrity policies. For this journal, that includes:
• Acknowledgements
• funding statement
• data availability statement
• conflict of interest disclosure
• ethics approval statement
• patient consent statement
• permission to reproduce material from other sources
• clinical trial registration

Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor. Do not include thanks to anonymous reviewers.

Research Funding

Journals should request that authors list all funding sources in their manuscript, in a dedicated funding section. The Open Funder Registry has information on correct nomenclature for authors to credit funding sources accurately. The role of the research funder beyond providing funding itself should also be described. It may be important to disclose, for example, if a commercial organization funded the study, designed the study, and also recruited the investigators. Other sources of support should be clearly identified in the funding section. For example, these might include funding for open access publication derived from a grant or from an author’s institution, or funding for writing or editorial assistance, or provision of experimental materials. If there is no specific funding this should be stated. List all funding sources in a separate Funding section on your title page.

You will be asked to provide your funding information at submission. You are responsible for making your funder’s credit accurate. If in doubt about how to do so, please check the Open Funder Registry for the correct nomenclature.

Conflicts of interest (COIs)

When submitting your manuscript, you must disclose any potential conflicts of interests (also referred to as "competing interests") that might appear to affect your or your co-authors' ability to present work objectively.

Potential conflicts of interest come in many forms and may include financial (for example, patent ownership, stock ownership, research funding, consultancies, or speaker's fees), intellectual, personal, political, ideological, or religious interests. Authors who are also Editors or members of the journal's Editorial Board should declare that here. You can read more about conflicts of interest in Wiley’s Best Practices for Research Integrity and Publishing Ethics.

Ethical Approvals and Statements

This journal requires you do the following, as appropriate:

• Provide Institutional Review Board (IRB) approvals
• Provide statements of ethical treatment of human and animal research participants
• Ensure informed consent has been obtained where necessary

Please review Wiley's guidelines surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines.

Cell Line Research

For papers containing cell lines, the following information should be provided in the Methods section.

• The species, sex, tissue of origin, official cell line name and Research Resource Identifier (RRID).
• Dates and timeline of described experiments, including passage number information (especially important for finite cell lines), may be requested.
• Avoid misspelled identifiers (e.g. the incorrect use of NKM45, in the place of MKN45).
• Official name and RRID are not applicable to primary cells.
• The source/supplier of the cell line and when it was obtained.
• Documentation of the origin may be requested, which should include details on the creation of in-house cell lines and where externally sourced cell lines were first established.
• Confirmation that the cell line was authenticated for the described experiments (inc. the % match result and method used) and has not been previously reported as misidentified or contaminated (see databases below).
• The expectation is that experiments were performed with verified cells (following STR profiling performed at the beginning and end of the described study), which are not listed within the databases below.
• Documentation for the % match result and dates of testing may be requested.
• Additional information on in-house or external testing may be requested.
• If the cell line is listed within the databases below, the rationale for its use must be provided. The use of cross-contaminated cell lines is not expected to be justifiable.
• Established cell lines without reference profiles require authentication to demonstrate no matches to other cell lines or evidence of being problematic.
• Confirmation that the cell line was free of mycoplasma contamination for the described experiments.
• The expectation is that experiments were performed with confirmed mycoplasma free cells (this includes cell lines used for virus production etc). At least the latest passage of the cell line (when the cells were used) must have been tested using cell pellets or cell samples (not supernatant) and confirmed negative.
• Documentation for mycoplasma result and dates of testing may be requested.
• Additional information on in-house or external testing may be requested.

If one or more of the above are unknown, this must be stated and the rationale for the use of the cell line provided. Further guidance on misidentification and contamination is available from the International Cell Line Authentication Committee (ICLAC) Register, the NCBI Misidentified Cell Line Database and Cellosaurus Problematic Cell Line Database.

Human Studies and Subjects

For manuscripts reporting studies which involve human participants:

• We require a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards.
  • The statement should also state clearly that all persons gave their informed consent prior to their inclusion in the study. Authors should be prepared to provide proof of consent documentation if requested.
• Patient anonymity should be preserved.
  • Non-essential identifying details in text and/or figures should be omitted. Eye bars should not be used as they are insufficient for de-identification. Images and information from individual participants (whether identifiable or not) will only be published where the authors have obtained the individual's free, prior-informed consent.
  • You do not need to provide a copy of the consent form; however, in signing the author license to publish, you are required to confirm that consent has been obtained.
  • Wiley has a standard patient consent form available for use.

You can learn more about the Human Studies and Subjects policy in Wiley's Best Practice Guidelines on Research Integrity and Publishing Ethics.

Cell line research

For manuscripts containing cell lines the following information should be provided in the methods section.

• The species, sex, tissue of origin, official cell line name and Research Resource Identifier (RRID).
  • Dates and timeline of described experiments, including passage number information (especially important for finite cell lines), may be requested.
  • Avoid misspelled identifiers (e.g. the incorrect use of NKM45, in the place of MKN45).
  • Official name and RRID are not applicable to primary cells.
• The source/supplier of the cell line and when it was obtained.
  • Documentation of the origin may be requested, which should include details on the creation of in-house cell lines and where externally sourced cell lines were first established.
• Confirmation that the cell line was authenticated for the described experiments (inc. the % match result and method used) and has not been previously reported as misidentified or contaminated (see databases below).
  • The expectation is that experiments were performed with verified cells (following STR profiling performed at the beginning and end of the described study), which are not listed within the databases below.
  • Documentation for the % match result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.
  • If the cell line is listed within the databases below, the rationale for its use must be provided. The use of cross-contaminated cell lines is not expected to be justifiable.
  • Established cell lines without reference profiles require authentication to demonstrate no matches to other cell lines or evidence of being problematic.
• Confirmation that the cell line was free of mycoplasma contamination for the described experiments.
  • The expectation is that experiments were performed with confirmed mycoplasma free cells (this includes cell lines used for virus production etc). At least the latest passage of the cell line (when the cells were used) must have been tested using cell pellets or cell samples (not supernatant) and confirmed negative.
  • Documentation for mycoplasma result and dates of testing may be requested.
  • Additional information on in-house or external testing may be requested.

If one or more of the above are unknown, this must be stated and the rationale for the use of the cell line provided. Further guidance on misidentification and contamination is available from the International Cell Line Authentication Committee (ICLAC) register, the NCBI misidentified cell line database and Cellosaurus problematic cell line database."

Clinical Trial Registry

This journal strongly recommends that clinical trials are registered in a publicly accessible database (e.g. ClinicalTrials.gov) before participants are enrolled.

You should include the name of the trial register and the clinical trial registration number at the end of your abstract.

If the trial is not registered, or was registered after participants were enrolled, you will need to explain why.

You can learn more about registering clinical trials in Wiley’s Best Practices Guidelines on Research Integrity and Publication Ethics.

Preregistration of studies

Authors are encouraged to indicate whether the conducted research was preregistered in an independent, institutional registry (e.g., http://clinicaltrials.gov/, https://www.socialscienceregistry.org/, http://osf.io/, https://egap.org/registry/, http://ridie.3ieimpact.org/). Preregistration of studies involves registering the study design, variables, and treatment conditions prior to conducting the research.

Preregistration of analysis plans

Authors are encouraged to indicate whether or not the conducted research was preregistered with an analysis plan in an independent, institutional registry (e.g., http://clinicaltrials.gov/, https://www.socialscienceregistry.org/, http://osf.io/, https://egap.org/registry/, http://ridie.3ieimpact.org/). Preregistration of studies involves registering the study design, variables, and treatment conditions. Including an analysis plan involves specification of sequence of analyses or the statistical model that will be reported.

Reporting guidelines

Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximize transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of:

• CONSORT for randomized controlled trials
• TREND for non-randomized trials
• PRISMA for systematic review and meta-analyses
• CARE for case reports
• STROBE for observational studies
• STREGA for genetic association studies
• SRQR for qualitative studies
• STARD for diagnostic accuracy studies
• ARRIVE for animal experiments

Reference Style

There is no submission requirement for formatting references.

We do ask that authors use a consistent reference style throughout the manuscript and include in a separate reference list:

• Author(s) name(s)
• Journal title/book title
• Article title (where applicable)
• Year of Publication
• Volume & Issue / Book Chapter
• Pagination
• Optional: DOI

If your manuscript is accepted for publication, we will update the formatting into the journal style.

Data Citation

Data must be cited just like articles, books, and websites. You are required to include data citations as part of their reference list.

You can choose to follow the format recommended in Wiley's Data Citation policy or use your preferred data citation format.

To learn more, you can review frequently asked questions about Data Sharing and Citation.

Data Sharing

This journal encourages data sharing.

You can learn more about data sharing in Wiley's Data Sharing Policies resource.

Data Availability Statement

You must include a data availability statement with your submission.

When submitting the manuscript you will be asked to select from several pre-written statements. If our standard templates do not match the circumstances of your data, you can use the text editor tool.

You can review Wiley’s Data Sharing Policies resource to understand which data availability statement is appropriate for your submission.

Figures

Figures should be provided in the highest resolution possible, whether this means they are embedded in the main document or provided separately.

Please review Wiley's general guidelines for figure preparation to learn more about preparing figures at different stages of the publishing process.

Figure Legends

All figures should have an accompanying figure legend that:

• describes the content
• explains any abbreviations or symbols
• clearly indicates which figure it explains
• If a copyrighted figure is reproduced with permission from another publication, a permission statement must be included and appropriate information submitted with the manuscript.

If a figure is reproduced from an open access (OA) article, whether the author’s own or not, the author must abide by the applicable license requirements of the original publication. See also under the section "Reproduction of copyrighted material".

Use Arabic numerals to label each figure and legend in the order that they appear in your main document (for example, "Figure 1" and "Figure 1 Legend").

If you embed figures in the main document, you may include the figure legend below each figure. If you upload your figures at submission, you may provide all figure legends in a separate "Figure Legend" section in the main document after the references.

Supporting Materials

Supporting materials and appendices should be provided as separate files.

For help providing supporting materials, you can view Wiley’s FAQs about supporting materials.

Embedded video and audio files

Authors can embed rich media (i.e., video and audio) within their final article.

These files should be submitted with the other submission files using either the "Embedded Video" or "Embedded Audio" file designation.

All embedded rich media will be subject to peer review.

For more detailed instructions, you can read the Embedded Rich Media Author Submission Guidelines.

Graphical abstract/graphical table of contents

This journal requires a graphical abstract: a single, concise figure that serves as a visual summary of the main research findings described in your manuscript.

Graphical abstracts should be provided in the highest resolution possible following Wiley's general guidelines for figure preparation.

In addition to our general guidelines, the graphical abstract must meet the following requirements:

• Color: use palettes and color combinations that are accessible to readers who are colorblind.
• Permissions: you are responsible for obtaining permission to use any images from outside sources.

Recommendations: use a simple graphic that is easy to follow by reading it either left to right or from top to bottom. Do not use data-heavy tables and avoid jargon or abbreviations that make it difficult for a reader to understand the main message of your abstract.

Plain Language Summary

This journal requires Plain Language Summaries for Original Research and Short Communication.

The Plain Language Summary (PLS) should convey the same information as the Abstract but in a completely different language and tone.

• It should summarize your research study, its results, and their broader relevance without using jargon so that it is broadly understandable by researchers outside your discipline, including research journalists, and research educators.
• The PLS should be a single paragraph and no more than 200 words long.

Wiley Editing Services offers a plain language summary service if you would like support in conveying the essentials of your research to a wider audience.

ORCiD ID

This journal requires the submitting author and all authors to provide their ORCiD ID — a unique, persistent identifier available at no charge to researchers.

The submitting author can provide this information in the submission system.

To support transparency and consistency across journals, the following descriptors are used:

• ORCiD policy: ORCiD ID required
• Who must provide: the submitting author
• Where to provide: in the submission system

You can refer to Recognition for Reviewers or the ORCiD website to create or check your identifier number.

Disclosing the Use of Artificial Intelligence (AI)

If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section.

Find more details in Wiley's AI policy in full in the Best Practices Guidelines on Research Integrity and Publishing Ethics.

Find more details in Wiley's AI Guidelines for Researchers and Wiley's AI policy in full in the Best Practices Guidelines on Research Integrity and Publishing Ethics.

Reproduction of Copyrighted Material

If you have included excerpts from copyrighted works owned by third parties, all sources must be credited within the manuscript. At minimum, the title and author should be provided.

You are responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source and for supplying Wiley with that permission upon submission.

For more information, you can review Wiley's Guidelines for Obtaining Permission to Reproduce Material.

Author pronouns

You can include your pronouns in the author bylines of published articles and on Wiley Online Library. You will never be required to include your pronouns but will always have the option to do so.

Pronouns can be included in your manuscript at submission and can be added, edited, or removed at any stage on request. No author should ever add, edit, or remove a co-author's pronouns without that co-author's consent.

Post-publication changes to pronouns can be made without a correction notice to the paper to protect the author's privacy, per Wiley's Name Change Policy.

Terms that fall outside of the scope of personal pronouns (e.g., proper or improper nouns) are not currently supported.

Nomenclature and Databank Registration

Species names

On its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses.

For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

Genetic nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate.

Human gene names should follow the recommendations provided by the HUGO Gene Nomenclature Committee whenever possible.

Gene names in other organisms should follow the appropriate standards within the field of research. The HUGO website offers some limited information on other species.

Sequence variant nomenclature must follow the current Human Genome Variation Society guidelines. Examples of acceptable nomenclature are provided on the HGVS nomenclature website.

Resource Identification Initiative

This journal supports the Resource Identification Initiative, which aims to promote research resource identification, discovery, and reuse.

This initiative, led by the Neuroscience Information Framework and the Oregon Health & Science University Library, provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

If there is a resource that is not found within the Research Resource Identification Portal, please register the resource with the appropriate resource authority. Information on how to do this is provided in the "Resource Citation Guidelines" section of the RRI Portal.

If you need help obtaining identifiers, please contact rii-help@scicrunch.org.

Sequence data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank.

It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis.

The suggested wording for referring to accession-number information is: "These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345".

Addresses:

• DNA Data Bank of Japan (DDBJ): ddbj.nig.ac.jp
• EMBL Nucleotide Archive: ebi.ac.uk/ena
• GenBank: ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories:

• Protein Information Resource (PIR): pir.georgetown.edu
• SWISS-PROT: expasy.ch/sprot/sprot-top

Structural data

For papers describing structural data, the atomic coordinates and associated experimental data should be deposited in the appropriate databank.

Please note that the data in databanks must be released, at the latest, by article publication. We trust our authors to ensure that atomic coordinates and experimental data are released on time.

Databanks:

• Organic and organometallic compounds: Crystallographic data should not be sent as supporting materials, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) (ccdc.cam.ac.uk/services/structure%5Fdeposit)
• Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; fiz-karlsruhe.de)
• Proteins and nucleic acids: Protein Data Bank (https://www.rcsb.org/)
• NMR spectroscopy data: BioMagResBank (bmrb.wisc.edu)

Preparing your revision

A revised submission should include all the elements of an initial submission (outlined in the "Preparing your submission" section). In addition, you should provide the following:

Tracked Changes Document

If you are asked to revise your submission, you need to provide a version of it that tracks any changes made since the last submission.

Author Response Letter

When returning a revised submission, you should include a letter that responds to the reviewer and editor comments.

This can be uploaded as a separate document when returning your revision.

High-resolution figures

If you did not provide high-resolution figures at initial submission, you should do so at revision. Figures can be embedded in the main document or provided separately as long as they are in the highest resolution possible.

You can review Wiley's general guidelines for figure preparation to learn more about providing high resolution figures.

Research Integrity and Publication Ethics

Authorship

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version.

You can review the Authorship section of Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics for more information.

Correction to Authorship

This journal allows authors to correct authorship on a submitted, accepted, or published manuscript if there is a valid reason to do so.

All authors, including those to be added or removed, must agree to any proposed change.

To request a change to the author list, please:

• Complete the Request for Changes to a Journal Article Author List Form. Authorship changes will not be considered without a fully completed Author Change form.
• If the manuscript is still in peer review, email the form to the journal's Editorial Office: tcres@pub.hep.cn
• If the manuscript has been accepted, email the form to the journal's Production Office: tcr4prod@wiley.com

This process follows Wiley's Best Practice Guidelines on Research Integrity and Publishing Ethics and guidance from the Committee on Publication Ethics (COPE).

Note: Correcting the authorship is different from changing an author's name. See "Author Name Change Policy" for details on that process.

Pending Patent Filings and Media Embargoes

On submission of a manuscript, authors confirm that any patent filings related to the content are complete and there are no media or other embargoes. Wiley will proceed with publication of accepted articles without delay or liability related to pending patent filings or embargoes. This policy applies even if any representative of Wiley, including employees or contractors, provides alternative guidance to the author.

Appeals and Complaints

You may appeal an editorial decision if you feel that the decision to reject was based on:

• a significant misunderstanding of a core aspect of the submission
• a failure to understand how the submission advances the literature
• concerns regarding the submission-handling process

Differences in opinion regarding the novelty or significance of the reported findings are not considered grounds for appeal.

To raise an appeal, please email the journal's Editorial Office. In the email, provide the manuscript ID number and your rationale for the appeal. The editor's decision following an appeal consideration is final.

To raise a complaint regarding editorial staff, policy, or process, please contact the journal. If you believe further support outside the journal's management is necessary, please refer to Wiley's Best Practice Guidelines on Research Integrity and Publishing Ethics.

COPE

This journal adheres to the ethical standards set by the Committee on Publication Ethics (COPE) to uphold integrity in scholarly research and publishing. While COPE previously organized its guidance around "core practices," these have since been replaced with a topic-based structure to better reflect the evolving needs of the research community. You can learn more about this transition and explore COPE's current guidance.

This journal uses screening approaches, for example, to check content for originality, data manipulation, and image manipulation. Any concerns raised via the use of screening software, or from editors, peer reviewers, or third parties, will be followed up by the journal in accordance with COPE Guidelines.

You can read Wiley’s Top 10 Publishing Ethics Tips for Authors and Best Practice Guidelines on Research Integrity and Publishing Ethics for more information on publication ethics.

Data Protection

Personal contact information provided when you submit a manuscript for this journal will only be used for the regular operations of the publication.

You can review Wiley's Privacy Policy to learn more.

Special Issues

All Special Issues published by this journal are reviewed and approved by the Editorial Board. This approval process includes an assessment of the rationale and scope of the proposed topic(s), and the expertise of Guest Editors, if any are involved. Special Issue articles must follow the same policies as described in the Author Guidelines. The Editor-in-Chief is responsible for the content of all Special Issues.

After Acceptance

Requests from the Editorial Office

After an article is accepted, the files will be assessed by the Editorial Office to ensure they are ready for production. You will be contacted if any updates or final files are required.

Registering for Wiley Author Services

When Wiley’s production team receives an accepted article, you will receive an email asking you to log in or register with Wiley Author Services.

You will be asked to sign a publication license at this point as well as pay for any applicable Article Publication Charges (APCs).

Note: You may be eligible for APC waivers or discounts through your institution, funder, or a country waiver. Please read more about this on Wiley’s APC information page.

Proofs

You will receive an e-mail notification with a link and instructions for accessing page proofs online. Proofs must be returned within 48 hours of receipt of the email. Please check your proof for errors only — rewriting of material is not feasible at this stage.

You should also make sure that any re-numbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures.

Early View publication

When proofing and production are complete, the final typeset version of the article is available as full-text HTML or PDF in Early View prior to inclusion in an issue. The article can then be cited as a reference using its Digital Object Identifier (DOI) number.

Article promotion support

You can read the Wiley Promotion Guide to learn more about available resources to maximize the impact of your article after publication.

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research — so you can help your research get the attention it deserves.

Publication-related charges

Open access

This is an open access journal. Submissions will be subject to an Article Publication Charge (APC) if accepted and published in the journal.

Please read more about APCs and whether you may be eligible for waivers or discounts through your institution, your funder, or a country waiver at Wiley Author Services.

Copyright and licensing

This is an open access journal. Authors of accepted papers pay an Article Publication Charge (APC) and their papers are published under a Creative Commons (CC) license.

For more information on this journal's APCs and licensing policy, please visit this journal's Open Access page.

Note: Some funders require authors to use a particular type of CC license. Please check directly with your funder to determine whether you must publish your article under a specific license. You can also use the Author Compliance Tool to find out which funders have CC license type restrictions. You will receive a link to select and sign a CC license only if your article is accepted for publication.

Self-Archiving definitions and policies

This journal's standard copyright agreement allows for self-archiving of different versions of the article under specific conditions.

You can learn more by reading Wiley's self-archiving policy.

Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services.

Our editorial and production teams will use discretion, since we recognize that name changes may be of a sensitive and private nature.

Accordingly, to protect the author's privacy, we will not publish a correction notice to the paper and we will not notify co-authors of the change.

Authors should contact the journal's Editorial Office with their name change request.

Contact support

If you have additional questions for the Editorial Office, please contact neurodrugdiscovery@oasepublish.com.

For technical help with the submission system, please review the Wiley Authors Submission Help Documents or contact submissionhelp@wiley.com.

Last updated: 26 May 2026